Companies researching Ocrevus (ocrelizumab)
Ocrevus (ocrelizumab) is a humanized anti‑CD20 monoclonal antibody employed as an immunosuppressive therapy for multiple sclerosis.
32
companies
List of companies that research Ocrevus (ocrelizumab)
| Company | Country | Industry | Employees | Revenue | Technologies |
|---|---|---|---|---|---|
Australia | Hospitals and Health Care | 730 | Ocrevus (ocrelizumab) | ||
United States | Higher Education | 13k | $2.3B | Ocrevus (ocrelizumab) | |
United States | Hospitals and Health Care | 51 | $2M | Ocrevus (ocrelizumab) | |
Switzerland | Biotechnology Research | 104k | $68B | Ocrevus (ocrelizumab) | |
United States | Hospitals and Health Care | 201 | Ocrevus (ocrelizumab) | ||
United Kingdom | Hospitals and Health Care | 193k | $105B | Ocrevus (ocrelizumab) | |
United States | Hospitals and Health Care | 6.3k | $300M | Ocrevus (ocrelizumab) | |
United States | Biotechnology Research | 21k | $26B | Ocrevus (ocrelizumab) | |
United States | Professional Services | 2.7k | $400M | Ocrevus (ocrelizumab) | |
United States | IT Services and IT Consulting | 201 | $27M | Ocrevus (ocrelizumab) |
Showing top companies out of 32 that research Ocrevus (ocrelizumab). Get the full list on TheirStack.
Frequently asked questions









